Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma - European Medical Journal

Continue

Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma

Oncology
At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given